Browse by category

Two separate studies have report that GLP-1s are linked to fewer alcohol and substance related hospitalisations for people with alcohol or substance use dependence. In the first study, published in The Lancet Psychiatry, people with type 2 diabetes were hospitalised less frequently for alcohol or substance use disorders while undergoing treatment with GLP-1 receptor agonists, according to a large Swedish registry study involving the Central Institute of Mental Health (CIMH).